Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease Levodopa más benserazida de liberación controlada en el manejo de lasfluctuaciones motoras en la enfermedad de Parkinson.
Author
dc.contributor.author
Díaz Díaz, Marcela Cecilia
Author
dc.contributor.author
Chaná,
Admission date
dc.date.accessioned
2019-01-29T15:47:42Z
Available date
dc.date.available
2019-01-29T15:47:42Z
Publication date
dc.date.issued
1991
Cita de ítem
dc.identifier.citation
Revista medica de Chile, Volumen 119, Issue 9, 2018, Pages 1022-1028
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/162455
Abstract
dc.description.abstract
Ten advanced Parkinson pts (mean 8 years since diagnosis), 6 male and 4 female, 57 to 69 years old, mean 5.9 years on L-Dopa therapy, were put on Madopar HBS to assess the efficacy of the drug. All the pts had levodopa end-of-dose wearing-off type secondary motor fluctuations, 9 of them with dyskinesia and dystonia. Clinical evaluation was performed in basal conditions (pts on standard L-Dopa therapy) 1.6 and 12 months on Madopar HBS therapy. Parkinson signology was quantified with the modified Columbia scale (0 to 44), and motor fluctuations and dyskinesia with a scale 0 to 4 according to intensity and frequency. Pts received mean 1.150 mg. HBS daily dose plus 100 to 200 mg standard L-Dopa added to the early morning dose for a faster effect. At 12 months, a 60% decrease in "off" periods, a 50% decrease in feet dystonia, with no change in orofacial dystonia were observed. Dyskinesia decreased in intensity but not in frequency. There was a 50% decrease of Parkinson signology in "on" per
Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease Levodopa más benserazida de liberación controlada en el manejo de lasfluctuaciones motoras en la enfermedad de Parkinson.